Active Sites Display

WP_316118024.1:PROKKA_02566
Sequence length: 1569 aa
2 domain hit(s)
This protein was scanned against CAZyme family profile alignments to identify conserved domains. Each hit below shows a region of the query that aligns to a known CAZyme family. Within each family profile, certain residues are known or predicted to be catalytic — directly involved in the enzyme's chemical reaction. The sequence display compares these critical positions between the query protein and the family consensus:
Match: the query has the expected catalytic residue, suggesting this active site is conserved and likely functional.
Mismatch: the query has a different residue at this position, which may indicate altered activity, a non-functional site, or subfamily variation.
Gap: the catalytic position in the profile has no corresponding residue in the query alignment, suggesting a deletion or truncation in this region.
Match
Mismatch
Gap
Active Site Conservation Analysis
EntryClassNameDomain RangeCoverageConservationCat. SitesMatches
IPR002889CBMCarbohydrate-binding WSC1–156994.4%40.9%155
IPR006215GHGlycoside hydrolase, melibiase1505–156975%40%82
Domain coverage (1–1569 aa)
IPR002889 — Carbohydrate-binding WSC (domain 1–1569)
1 11 21 31 41 51 61 71 81 91 101 111 121 131 141 151 161 171 181 191 201 211 221 231 241 251 261 271 281 291 301 311 321 331 341 351 361 371 381 391 401 411 421 431 441 451 461 471 481 491 501 511 521 531 541 551 561 571 581 591 601 611 621 631 641 651 661 671 681 691 701 711 721 731 741 751 761 771 781 791 801 811 821 831 841 851 861 871 881 891 901 911 921 931 941 951 961 971 981 991 1001 1011 1021 1031 1041 1051 1061 1071 1081 1091 1101 1111 1121 1131 1141 1151 1161 1171 1181 1191 1201 1211 1221 1231 1241 1251 1261 1271 1281 1291 1301 1311 1321 1331 1341 1351 1361 1371 1381 1391 1401 1411 1421 1431 1441 1451 1461 1471 1481 1491 1501 1511 1521 1531 1541 1551 1561 Query: MNIEEGIENR VMNLNFKGKL NNGGYIMKSK KILKMYISLA LSCSIVFSNT SVLVNAIESR DRKVFANIGK DKISIGNDYI KREFSIDNGK VLTNLIENNR ANTTLIPGKG SEDFIINTIQ PEEDTDVEVP IEVIDRTSWN ATLTTSSNTE FLQENVKLLF DGDANTYIDQ YTITGYPISL KVDLGEEKKV SSFSYLKRPG YEDAAYGING TMGKYKLYVS DDGVNWKEAG EGEFKREDYN LHQEGKLQNV GDVVYGNFNK EYTTRYIRID QLSDSLGNTQ EFSASEINLY SDKYMEEEST VDDSKIESSE LTIDNETTKI ENIESGKKLT ISYLPYKLNG IEYNIDMVTV LKSNENYMRS FLEIKADNSK AQIDYIDLDK FVLEDEISDT VWSHPDLKDV SSMWIGKNEL MLGQPIYANG MFFGSEFPAA DTDVVDDEIQ IRYYSGKTFE KLAEDNQLTT DGKFVSWQNV VGAAKGTDTD VVQTDFYEYI SDIATPTEFR KQYNSWYDNM LEITDESIAK SFYGSEKGLT ENGVEPVDSY VVDDGWNNYR DEKYNPNISS SQSGEGMNRT GFWEFNSKFP NELYTSTELT NKFQSKFGIW LGPQGGYNYF SGFAKYMEES GTAYAQNDYW TNICVGSDKY VKNLTSMFID NQKRFDVDYW KIDGFAVRPC TNQKHDHMTG GTNNMYYTTD LWEKWTDAWE EMRASRAEEG KGLFINATCY VNLSPWLLQW VNTIWVQDSG DTGQAGTGER HQQKITYRDN VYYNLFKVNQ VQFPLKNIYN HDPIYGVSDG SSATTEDFRD FLFSNSVRGT AFWELYYSPS IMDDEKWKVN ADALEFAETN SHILEKAKLF GERPTQGVYG YSCWDGDEGI VSFRNPTEEE KEYTLELTDM VGVPKSVKDI KGNQVLPYVV GDSSTVSYGD TLTVKLAPYE TRIFQYGKND STGAEIISAK VTGNNEITVK YNERVENGKE VYSVEGNNIT ETKLLDDYRT VVITTKNRIV DKAKLNITGE RDAVGNKITK SLEIPAYSNG KVANVTSGNN LVDGENIEKS YNGDLDMFLL NLDKDYTLED NKSFTGTNDF AISMAVKTTS NNVNLLSQGD DISLSIDEEG YVSFKVKDLK VNSKSEVTTV IEKAHGIFGT DKYVPTSTSS SFVGKVNDGD LHQVVAVREV NGMLKIYIDG ELSNSVYDEN RINQSIESGK IVVADNSFKG ILGGIELRNS SIYYDEAKSM YEPFKGSEII EIDRSNWKAS ACSEMPATSG DGQASTAIDG NESSWWHTNY VGGDSHEGNH WIQVDFGDET SFDTINVLSR GKNSNGTIKD YKLDVKVNGQ WKEIKTGTFE SGINDSIIFE EAITASAIRI TALSTFNGKD FAAIKEITLT NKDRLATKEE IDDAKELVKD IDENNYTIVT AERYNEIALK LNLVSEINTI PLKKLIAQLE EAYSSLLDAK ELNDLLKEIN SLNKEEYTLE SWYNLENEVL KANAVVRDIY STEKDVSNSY KTLKETYNNL KLVGTGNNSN QGNDTNNGSG SEGNNTSKPT QTGDSSKGSL ALLGALLSVI SIFIFGKKR Profile: C········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········C ·N········ ·········· ·········· ·········· ········C· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· C·C······· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·CR······· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········C ·········· ·········· ·········· T·C······· ··Y···RDR
query > profileM1>C7C670>C35N672>N37C719>C40L1041>C57D1043>C59C1252>C77S1253>R78N1520>C82A1551>T92L1553>C93F1563>Y102K1567>R106K1568>D107R1569>R108
IPR006215 — Glycoside hydrolase, melibiase (domain 1505–1569)
Cross-ref: InterPro: IPR006215
GO: GO:0004557 alpha-galactosidase activityGO:0005975 carbohydrate metabolic process
1 11 21 31 41 51 61 71 81 91 101 111 121 131 141 151 161 171 181 191 201 211 221 231 241 251 261 271 281 291 301 311 321 331 341 351 361 371 381 391 401 411 421 431 441 451 461 471 481 491 501 511 521 531 541 551 561 571 581 591 601 611 621 631 641 651 661 671 681 691 701 711 721 731 741 751 761 771 781 791 801 811 821 831 841 851 861 871 881 891 901 911 921 931 941 951 961 971 981 991 1001 1011 1021 1031 1041 1051 1061 1071 1081 1091 1101 1111 1121 1131 1141 1151 1161 1171 1181 1191 1201 1211 1221 1231 1241 1251 1261 1271 1281 1291 1301 1311 1321 1331 1341 1351 1361 1371 1381 1391 1401 1411 1421 1431 1441 1451 1461 1471 1481 1491 1501 1511 1521 1531 1541 1551 1561 Query: MNIEEGIENR VMNLNFKGKL NNGGYIMKSK KILKMYISLA LSCSIVFSNT SVLVNAIESR DRKVFANIGK DKISIGNDYI KREFSIDNGK VLTNLIENNR ANTTLIPGKG SEDFIINTIQ PEEDTDVEVP IEVIDRTSWN ATLTTSSNTE FLQENVKLLF DGDANTYIDQ YTITGYPISL KVDLGEEKKV SSFSYLKRPG YEDAAYGING TMGKYKLYVS DDGVNWKEAG EGEFKREDYN LHQEGKLQNV GDVVYGNFNK EYTTRYIRID QLSDSLGNTQ EFSASEINLY SDKYMEEEST VDDSKIESSE LTIDNETTKI ENIESGKKLT ISYLPYKLNG IEYNIDMVTV LKSNENYMRS FLEIKADNSK AQIDYIDLDK FVLEDEISDT VWSHPDLKDV SSMWIGKNEL MLGQPIYANG MFFGSEFPAA DTDVVDDEIQ IRYYSGKTFE KLAEDNQLTT DGKFVSWQNV VGAAKGTDTD VVQTDFYEYI SDIATPTEFR KQYNSWYDNM LEITDESIAK SFYGSEKGLT ENGVEPVDSY VVDDGWNNYR DEKYNPNISS SQSGEGMNRT GFWEFNSKFP NELYTSTELT NKFQSKFGIW LGPQGGYNYF SGFAKYMEES GTAYAQNDYW TNICVGSDKY VKNLTSMFID NQKRFDVDYW KIDGFAVRPC TNQKHDHMTG GTNNMYYTTD LWEKWTDAWE EMRASRAEEG KGLFINATCY VNLSPWLLQW VNTIWVQDSG DTGQAGTGER HQQKITYRDN VYYNLFKVNQ VQFPLKNIYN HDPIYGVSDG SSATTEDFRD FLFSNSVRGT AFWELYYSPS IMDDEKWKVN ADALEFAETN SHILEKAKLF GERPTQGVYG YSCWDGDEGI VSFRNPTEEE KEYTLELTDM VGVPKSVKDI KGNQVLPYVV GDSSTVSYGD TLTVKLAPYE TRIFQYGKND STGAEIISAK VTGNNEITVK YNERVENGKE VYSVEGNNIT ETKLLDDYRT VVITTKNRIV DKAKLNITGE RDAVGNKITK SLEIPAYSNG KVANVTSGNN LVDGENIEKS YNGDLDMFLL NLDKDYTLED NKSFTGTNDF AISMAVKTTS NNVNLLSQGD DISLSIDEEG YVSFKVKDLK VNSKSEVTTV IEKAHGIFGT DKYVPTSTSS SFVGKVNDGD LHQVVAVREV NGMLKIYIDG ELSNSVYDEN RINQSIESGK IVVADNSFKG ILGGIELRNS SIYYDEAKSM YEPFKGSEII EIDRSNWKAS ACSEMPATSG DGQASTAIDG NESSWWHTNY VGGDSHEGNH WIQVDFGDET SFDTINVLSR GKNSNGTIKD YKLDVKVNGQ WKEIKTGTFE SGINDSIIFE EAITASAIRI TALSTFNGKD FAAIKEITLT NKDRLATKEE IDDAKELVKD IDENNYTIVT AERYNEIALK LNLVSEINTI PLKKLIAQLE EAYSSLLDAK ELNDLLKEIN SLNKEEYTLE SWYNLENEVL KANAVVRDIY STEKDVSNSY KTLKETYNNL KLVGTGNNSN QGNDTNNGSG SEGNNTSKPT QTGDSSKGSL ALLGALLSVI SIFIFGKKR Profile: ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ·········· ····NCYNK· ·········· ·········· ·········· ·········· ·········· ······T··
query > profileE1505>N1T1506>C2Y1507>Y3N1508>N4N1509>K5K1567>T10gap>S14gap>Y15
↑ Top





v1.01 @copyright 2026 UCLA